Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
Public ClinicalTrials.gov record NCT05753501. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies
Study identification
- NCT ID
- NCT05753501
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 135 participants
Conditions and interventions
Conditions
Interventions
- ABBV-101 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 8, 2023
- Primary completion
- Feb 28, 2031
- Completion
- Feb 28, 2031
- Last update posted
- Mar 26, 2026
2023 – 2031
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates, PC-HOPE /ID# 252351 | Tempe | Arizona | 85284-1812 | — |
| UC Irvine Medical Center /ID# 263020 | Orange | California | 92868-3201 | — |
| Stanford University /ID# 249683 | Palo Alto | California | 94304 | — |
| Rocky Mountain Cancer Centers - Lone Tree /ID# 252237 | Lone Tree | Colorado | 80124 | — |
| Northwestern University Feinberg School of Medicine /ID# 249347 | Chicago | Illinois | 60611-2927 | — |
| Beth Israel Deaconess Medical Center /ID# 249302 | Boston | Massachusetts | 02215-5400 | — |
| Rutgers Cancer Institute of New Jersey /ID# 249323 | New Brunswick | New Jersey | 08901 | — |
| New York Oncology Hematology - Albany Cancer Center /ID# 252240 | Albany | New York | 12206-5013 | — |
| Northwell Health - Monter Cancer Center /ID# 250422 | Lake Success | New York | 11042 | — |
| University of Rochester Medical Center /ID# 249324 | Rochester | New York | 14642-0001 | — |
| UC Health - Cincinnati /ID# 249299 | Cincinnati | Ohio | 45267-2800 | — |
| Oncology Assoc. of Oregon PC - WVCI and Research Ctr - Springfield /ID# 249309 | Eugene | Oregon | 97401-6036 | — |
| University of Pennsylvania /ID# 250341 | Philadelphia | Pennsylvania | 19104 | — |
| MD Anderson Cancer Center /ID# 249293 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05753501, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2026 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05753501 live on ClinicalTrials.gov.